Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
DeTemple VK, Kaatz M, Stockfleth E, Scheel C, Angela Y, Gutzmer R, Leiter U, Meier F, Schadendorf D, Livingstone E, Gebhardt C, von Wasielewski I, Weichenthal M, Mohr P, Hassel J, Pföhler C, Simon JC, Jochims F, Terheyden P, Ulrich J, Haferkamp S, Drexler K, Schilling B, Glutsch V, Heinzerling L, Berking C, Ugurel S, Tomsitz D.
DeTemple VK, et al.
Eur J Cancer. 2025 Jul 25;225:115590. doi: 10.1016/j.ejca.2025.115590. Epub 2025 Jun 24.
Eur J Cancer. 2025.
PMID: 40580809
Free article.